Tirzepatide denied as experimental or investigational by Anthem?

Anthem's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied Tirzepatide as Experimental

An experimental or investigational denial from Anthem means the plan has determined — for the specific indication on your claim — that the evidence does not meet its threshold for coverage as an established medical treatment. For tirzepatide, this denial most frequently arises when the prescription is for an indication that Anthem's current clinical policy has not yet recognized, or when a plan's medical policy lags behind a recent FDA approval. It can also occur when a plan interprets an on-label indication narrowly.

This denial is directly challengeable when tirzepatide's use falls within its FDA-approved labeling. FDA approval is the foundational standard for established treatment, and a denial that contradicts that approval is vulnerable to reversal at internal appeal or, if needed, at independent external review.

## Your Appeal Rights

• ACA §2719 / ERISA §503: Federal law guarantees a full-and-fair internal appeal and independent external review for most non-grandfathered group and individual-market plans.
• Internal appeal deadline: Typically 180 days from the denial date; confirm the exact deadline on your Anthem denial letter or Explanation of Benefits.
• External review window: Approximately four months from the date of a final adverse internal determination to file for independent external review.
• Expedited review: If delay poses an urgent risk to your health, request expedited internal and external review simultaneously in writing; federal law sets shortened decision timelines.

## Documentation to Gather

1. FDA prescribing information: Obtain the current official FDA label for tirzepatide. Identify the approved indication(s) and confirm your prescription is for an on-label use. Attach or reference the relevant section in your appeal. 2. Diagnosis confirmation: Current chart documentation clearly establishing your diagnosis in terms that align with the FDA-approved indication. 3. Professional society guideline support: Ask your prescriber to reference — without citing specific trial statistics or numbers — that a recognized professional organization (such as the American Diabetes Association, the Obesity Society, or an applicable ACC/AHA guideline body) includes tirzepatide as a recognized treatment option for your condition. 4. Prescriber medical-necessity letter: Your treating clinician should state plainly that this is on-label, guideline-supported treatment, explain the clinical necessity for your specific case, and address Anthem's experimental characterization directly. 5. Insurer policy mapping: Obtain Anthem's current published clinical policy for tirzepatide. Note the policy's effective or review date. If the policy predates the relevant FDA approval, cite that gap explicitly in your appeal letter.

## Criteria-Mapping Structure

Frame your appeal as a direct rebuttal: Anthem's stated basis for experimental classification | FDA approval status and label reference | Clinical guideline recognition (organization name only) | Chart evidence confirming on-label use. If Anthem's policy version is older than the current FDA label, document the date discrepancy and request that the reviewer apply the current policy — or acknowledge that no current policy exists that supports the experimental classification.

Always verify the current FDA-approved indications from the official prescribing information and confirm Anthem's most recently published clinical policy version before finalizing your submission.